Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme presents new positive data on Carticel
These findings revealed that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost
These findings revealed that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost
Under the first transaction, NuVasive has satisfied all remaining royalty obligations for its SpheRx platform of products for a single cash payment of $3.25 million. The transaction provides
The transaction contemplates the sale of specific assets and commercial operations in Italy, as well as the sale of its German subsidiary Adaltis Deutschland. The selling price agreed
The new data builds on earlier work by lead investigator, Kenneth Shindler in the same preclinical model showing that activation of the SIRT1 enzyme with SRT501 is neuroprotective
The data suggests that the use of company’s biomarkers could help better identify women with ovarian cancer, as well as improve the detection of early-stage disease. A clinical
The study will be conducted in France and is designed as a two-stage study with potential enrolment of up to 27 patients. The primary endpoint will be the
Dyloject will be available at the National Health Service tariff price of GBP48 per pack (10 x 75mg/2ml vials). The SMC has said that the manufacturer’s submission related
Under the term sheet, Medpharm will be acquired for $1.5 million. Symbollon will acquire approximately 64% of the company in a stock swap for Symbollon shares and acquire
Bard’s Access Systems subsidiary, located in Salt Lake City, Utah, will assume marketing responsibility for the related products. The company expects to complete the transaction following approval by
New investor MedImmune Ventures joined previous investors Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and Neuro Ventures in the round. As a part of the